ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2204

Guidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2342

Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2335

Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1969

Harmonising Consensus and Reliability Studies in Musculoskeletal Ultrasound

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1913

Health Literacy and Disease, Clinical, Functional and Management Outcomes in Inflammatory Arthritis: A Systematic Literature Review

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 1931

Health System Improvement in Appropriate Test Utilization Involving ANA Testing in the Inpatient and Outpatient Setting

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2015

Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2403

Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1916

Healthcare Disparities and Clinical Outcomes in Cardiac Sarcoidosis. a Retrospective Cohort Study

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 1958

Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1886

Heterogeneity of VEXAS Syndrome: A Multicenter Case-series of 299 Cases from the French VEXAS Study Group (FRENVEX)

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1802

Heterogeneous Neutrophil Subsets Infiltrate Glomeruli of Lupus Nephritis Patients and Are Elevated in the Kidneys and Urine of Sunlight-induced Nephritis Flares

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2456

High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1887

High Rates of Cost-Related Medication Non-Adherence Among Younger Patients Receiving Immunosuppression Are Exacerbated by Other Chronic Conditions

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2474

High-throughput Screening Identifies Specific Molecular Markers for ILD in Patients with Rheumatic Diseases

Systemic Sclerosis & Related Disorders – Clinical Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].